
Nobel Therapeutics Private Limited
Founded in 2013 and headquartered in Gujarat, India.
Founded in 2013 and headquartered in Gujarat, India.
Vadodara, Gujarat, India
+91-XXXXXXXXXX
U24232GJ2013PTC074684
074684
Private Limited Indian Non-Government Company
23 Apr 2013
30 Sep 2018
31 Mar 2018
Unlisted
Roc Ahmedabad
Name | Designation | Appointment Date | Status |
---|---|---|---|
Bhavnaben Shah ![]() | Director | 23-Apr-2013 | Current |
Rakeshkumar Shah ![]() | Director | 23-Apr-2013 | Current |
Nobel Therapeutics Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets | |||||||
Profit or Loss | |||||||
Net Worth | |||||||
EBITDA |
In 2017, Nobel Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Rakeshkumar Shah is a mutual person
Bhavnaben Shah and Rakeshkumar Shah are mutual person
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Nobel Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Nobel Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nobel Therapeutics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Nobel Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2018 as per latest MCA records.
Nobel Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2018 with Roc Ahmedabad.
Bhavnaben Rakeshkumar Shah was appointed as a Director was appointed as a Director on 23 Apr 2013 & has been associated with this company since 12 years 1 month .
Rakeshkumar Govindlal Shah was appointed as a Director was appointed as a Director on 23 Apr 2013 & has been associated with this company since 12 years 1 month .
Nobel Therapeutics Private Limited was registered on 23 Apr 2013 with Roc Ahmedabad & aged 12 years 1 month as per MCA records.
Nobel Therapeutics Private Limited was incorporated on 23 Apr 2013.
The authorized share capital of Nobel Therapeutics Private Limited is ₹ 1.00 M and paid-up capital is ₹ 0.10 M.
Currently 2 directors are associated with Nobel Therapeutics Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Nobel Therapeutics Private Limited is 102 Girikandara Apartment Near Bapod Talav Waghodiya Road, India, Vadodara, Gujarat, 390019.
The corporate identification number (CIN) of Nobel Therapeutics Private Limited is U24232GJ2013PTC074684 and the company number is 074684 as per Ministry of Corporate Affairs (MCA).
The most recent Balance Sheet for Nobel Therapeutics Private Limited was filed with the ROC on 31 Mar 2018.
Search company & director profiles for free and gain access to critical business data.